Phase 3 trial: Imatinib mesylate, a Bcr-Abl/c-KIT/PDGF inhibitor, in Ph+ ALL.

Children’s Oncology Group is evaluating imatinib mesylate with varied chemotherapy regimens—with or without stem cell transplant—to treat newly diagnosed Philadelphia chromosome–positive and ABL-class fusion positive acute lymphoblastic leukemia. The trial aims to identify regimens that preserve efficacy while reducing side effects compared to stronger chemotherapy backbones.